Shopping Cart
- Remove All
Your shopping cart is currently empty
PPARγ-IN-3
Catalog No. T89904
PPARγ-IN-3 (compound 9ga), a potent and orally active PPARγ inhibitor, effectively reduces triglyceride (TG) accumulation and exhibits low cytotoxicity. Additionally, it prevents excessive body weight gain, lessens fat and liver mass, and decreases lipid accumulation in both the liver and blood. PPARγ-IN-3 holds promise for research into diet-induced obesity.
PPARγ-IN-3
PPARγ-IN-3
Catalog No. T89904
PPARγ-IN-3 (compound 9ga), a potent and orally active PPARγ inhibitor, effectively reduces triglyceride (TG) accumulation and exhibits low cytotoxicity. Additionally, it prevents excessive body weight gain, lessens fat and liver mass, and decreases lipid accumulation in both the liver and blood. PPARγ-IN-3 holds promise for research into diet-induced obesity.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | Backorder | |
| 50 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PPARγ-IN-3"
2,3-Butanediol
T19094513-85-9
2,3-Butanediol, derived from the bioconversion of natural resources, holds significant potential for various industries, including chemical, cosmetics, agriculture, and pharmaceutical sectors.
- $40
Size
QTY
Fenofibrate
Cited
Procetofen, Lipantil, Lipanthyl
T114949562-28-9
Fenofibrate (Lipanthyl) is a PPARα agonist (EC50=30 μM) and is selective. Fenofibrate also inhibits cytochrome P450 isoforms, such as CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4. Fenofibrate exhibits antihyperlipidemic activity.
- $32
Size
QTY
CitedPioglitazone hydrochloride Cited
U-72107E, U 72107A, Pioglitazone HCl, AD 4833
T0214L112529-15-4
Pioglitazone hydrochloride (AD 4833) is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
- $35
Size
QTY
Cited
(S)-(+)-Ibuprofen
Dexibuprofen, (S)-Ibuprofen
T044851146-56-6
(S)-(+)-Ibuprofen (Dexibuprofen) , is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
- $35
Size
QTY
Gemfibrozil
Lopid, Jezil, Decrelip, CI-719
T141525812-30-0
Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).
- $30
Size
QTY
Clofibric acid Cited
Chlorofibrinic acid
T0061882-09-7
Clofibric acid (Chlorofibrinic acid) is an antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
- $31
Size
QTY
CitedClofibrate
Ethyl clofibrate, Clofibratum, Clofibrato
T1298637-07-0
Clofibrate (Clofibrato) is an aryloxyisobutyric acid derivate with antihyperlipidemic activity.
- $30
Size
QTY
Cloxiquine
Dermofungin, Dermofongin, 5-Chloro-8-quinolinol
T0509130-16-5
Cloxiquine (Dermofongin) is a monohalogenated 8-hydroxyquinoline with activity against bacteria, fungi, and protozoa.
- $31
Size
QTY
Fenofibric acid
Trilipix, NSC 281318, FNF acid
T140242017-89-0
Fenofibric acid (FNF acid) is the active form of fenofibrate, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity.
- $33
Size
QTY
Muraglitazar
Pargluva, BMS-298585
T21587331741-94-7In house
Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα and PPARγ with EC50 of 320 nM and 110 nM respectively.
- $293
Size
QTY
Repaglinide Cited
AG-EE 623ZW, AG-EE 388 ZW
T1088135062-02-1
Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury.
- $43
Size
QTY
CitedContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | PPARγ-IN-3 (compound 9ga), a potent and orally active PPARγ inhibitor, effectively reduces triglyceride (TG) accumulation and exhibits low cytotoxicity. Additionally, it prevents excessive body weight gain, lessens fat and liver mass, and decreases lipid accumulation in both the liver and blood. PPARγ-IN-3 holds promise for research into diet-induced obesity. |
| Molecular Weight | 469.51 |
| Formula | C23H28FN7O3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PPARγ-IN-3 | purchase PPARγ-IN-3 | PPARγ-IN-3 cost | order PPARγ-IN-3 | PPARγ-IN-3 formula | PPARγ-IN-3 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.